Business Context and Reporting Period
This Form 8-K was filed by AIT Therapeutics, Inc. on February 26, 2019, reporting events that occurred on January 23, 2019, and February 1, 2019. The Company is an emerging growth corporation incorporated in Delaware.
Key Financial Metrics
The filing details a strategic partnership involving equity consideration rather than immediate cash revenue. Key metrics include:
- Milestone Payments Received: The Company received ordinary shares of Circassia Limited valued at $7,350,000 on January 23, 2019, and $3,150,000 on February 1, 2019.
- Total Equity Consideration: $10,500,000 in Circassia shares.
- Valuation Method: Shares were valued at a 5% discount to the lower of the one-week or one-month average weighted market price of Circassia shares prior to January 23, 2019.
- Cash Flow and Debt: The filing text does not provide specific values for cash flow, debt, or liquidity positions, though a pro forma balance sheet is referenced as an exhibit.
Material Changes
The primary material change is the execution of a License, Development and Commercialization Agreement with Circassia Limited. Under this agreement, AIT Therapeutics granted Circassia an exclusive, royalty-bearing license to distribute, market, and sell AIT's nitric oxide generator and delivery system in the United States and China. This transaction resulted in the receipt of significant equity assets from Circassia.
Outlook, Risks, and Unusual Items
Management Commentary: The transaction represents a strategic expansion of the Company's commercial reach into the US and Chinese markets through a partner.
Unusual Items: The consideration for the license was paid entirely in equity (Circassia shares) rather than cash, which impacts the Company's asset composition and potential future liquidity depending on the performance of Circassia's stock.
Risks: The filing does not explicitly list new risks, though reliance on a third party for commercialization and the volatility of the equity received are inherent considerations.
Investor Verification Checklist
- Verify the current market price of Circassia Limited shares to assess the current value of the $10.5 million equity stake received.
- Review the attached Exhibit 99.1 (Pro Forma Balance Sheet) to understand the impact on the Company's total assets and equity as of December 31, 2018.
- Confirm the specific royalty terms and future milestone triggers within the full text of the License, Development and Commercialization Agreement.
- Check for any lock-up periods or restrictions on the sale of the Circassia shares received.